Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Merck Serono Initiates Phase III Study Of Stimuvax In Breast Cancer
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the initiation of its global Phase III clinical study of the therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. The STRIDEa study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study. The STRIDE study will be supervised by an expert Steering Committee and is sponsored by Merck Serono, which is leading the development of Stimuvax.
generic viagra online
Quality Of GP Consultations Drives High Patient Satisfaction, UK
Being given enough time with a GP and feeling that their problems are taken seriously are the most important factor in patients" satisfaction with their local surgery, according to new data out today. The GP Patient Survey, the biggest healthcare survey of its kind, found that overall satisfaction with surgeries was high at 91%, but there is still room for improvement in accessing GP services, especially getting through on the phone and being able to make appointments more than 48 hours in advance.
News of the day
What Is Croup? What Causes Croup?
Croup is a common respiratory condition characterized by inflammation of the upper airways that often occurs in infants and children. The result is a swelling and narrowing of the larynx (voice box) and trachea (wind pipe) that results in a harsh, barking cough.
Cardiovascular

Microbicide Under Research For HIV Prevention Examined

A team of researchers from the University of Pittsburgh, the University of Missouri and Japan has been studying a compound they believe might prevent HIV transmission, the Columbia Tribune reports. According to the Tribune, "Tests show the microbicide, known as EFdA, stops HIV from replicating or spreading when applied to human cells." Stefan Sarafianos, assistant professor of microbiology and immunology at the University of Missouri"s School of Medicine, and a researcher working on the compound, said, "Women would be able to apply it to themselves and have control over the situation, unlike other forms of protection," adding that although the compound is in an early stage of research, "hopefully companies will eventually license and develop it as a product." The article also discusses findings from a study by an Indiana University School of Medicine researcher that "found that students who know their lifestyle puts them at risk for sexually transmitted diseases would be more likely to receive an HIV vaccination" if it were available, but that they would be less likely to get a vaccine if they are worried about what others might think of them (Heavin, 8/3). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009